DEXCOM INC — Director's Dealing 2018

Mar 14, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2018-03-12

Reporting Person: Balo Andrew K (EVP, Reg. Strategy, Clinical)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-03-12	Common Stock	D	2834	$60.7306	Disposed	115252	Direct
2018-03-12	Common Stock	D	2221	$60.7306	Disposed	113031	Direct
2018-03-12	Common Stock	D	4464	$60.7306	Disposed	108567	Direct

Footnotes

F1: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted.

F2: Included in this number are 70,343 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 19,174 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 12,667 of which were granted on March 8, 2016 and shall vest through March 8, 2019.